psychedelics investing Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression Awareness Day
psychedelics investing Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia
psychedelics investing Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
psychedelics investing Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
psychedelics investing Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
psychedelics investing Compass Pathways Launches 'Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
psychedelics investing Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
psychedelics investing Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways to Participate in Investor Conferences the Week of September 14th
psychedelics investing Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
psychedelics investing Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
psychedelics investing Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
